A Look At Chugai Pharmaceutical (TSE:4519) Valuation After Recent Share Price Softness

Why Chugai Pharmaceutical Stock Is On Investors’ Radar

Chugai Pharmaceutical (TSE:4519) has attracted attention after recent share price moves, with a 1 day return of about a 1.5% decline and a roughly 1.6% decline over the past week prompting closer scrutiny.

These shorter term returns sit against a 1 month return of about an 8.7% decline and a past 3 months gain of roughly 2.6%, which provides a mixed but measurable recent performance profile to assess.

See our latest analysis for Chugai Pharmaceutical.

At a share price of ¥8,640.0, Chugai’s recent share price return has softened in the short term, but the 1-year and multi year total shareholder returns indicate momentum that has been strong over a longer horizon.

If you are comparing Chugai’s story with other healthcare names using AI or advanced therapies, it can be useful to scan 8 healthcare AI stocks

With Chugai trading at ¥8,640 and sitting at a discount to some analyst price targets and intrinsic estimates, the key question is whether the current valuation leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 1% Overvalued

Chugai’s most followed narrative puts fair value at about ¥8,571, just under the last close at ¥8,640. This suggests a relatively narrow valuation gap.

The analysts have a consensus price target of ¥8082.143 for Chugai Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥10800.0, and the most bearish reporting a price target of just ¥6100.0.

Read the complete narrative.

Want to understand why this fair value sits only a touch below today’s price? The narrative places emphasis on steady revenue gains, higher margins and a richer future earnings multiple. Curious how those three elements could develop over the next few years and what they might imply for long-run cash flows? The full story connects each assumption directly to that ¥8,571 figure.

Result: Fair Value of ¥8,571 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there is still clear execution risk around the heavy reliance on Hemlibra and Actemra, as well as the potential for pricing pressure to squeeze margins over time.

Find out about the key risks to this Chugai Pharmaceutical narrative.

Another View: Market Ratios Paint A Richer Picture

Analyst narratives suggest Chugai is only about 1% overvalued against a fair value of ¥8,571, yet the current P/E of 32.8x sits roughly double the JP Pharmaceuticals average of 16x and slightly above the 31.7x peer average, even though the fair ratio is 39x. Is the market paying up for quality, or stretching too far on sentiment?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment in this article leaning cautiously positive, it can help to move quickly, review the underlying numbers yourself, and form an independent view using the 3 key rewards

Looking for more investment ideas?

If Chugai has your attention but you want broader options, use curated stock lists to quickly surface ideas that might better match your goals and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com